| Erin Carlyle Hall, MD | |
|
110 Irving St Nw, Washington, DC 20010-3017 | |
| (202) 877-5190 | |
| (202) 877-3173 |
| Full Name | Erin Carlyle Hall |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 17 Years |
| Location | 110 Irving St Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356582001 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD040810 (Maryland) | Secondary |
| 2086S0127X | Surgery - Trauma Surgery | D0079340 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medstar Washington Hospital Center | Washington, DC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Whc Physician Group Llc | 6103093513 | 312 |
News Archive
The monoclonal antibody omalizumab seems to be effective at relieving symptoms for patients with chronic idiopathic urticaria who have not responded to H1-antihistamine therapy, report US researchers.
Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.
The U.S. Food and Drug Administration announced today that it has scheduled a public meeting on Feb. 18, 2010, to discuss key challenges related to the premarket notification, or 510(k) process, used to review and clear certain medical devices marketed in the United States. The FDA receives more than 3,000 510(k) submissions each year.
The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's disease.
› Verified 3 days ago
| Entity Name | Whc Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700154226 PECOS PAC ID: 6103093513 Enrollment ID: O20120125000252 |
News Archive
The monoclonal antibody omalizumab seems to be effective at relieving symptoms for patients with chronic idiopathic urticaria who have not responded to H1-antihistamine therapy, report US researchers.
Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.
The U.S. Food and Drug Administration announced today that it has scheduled a public meeting on Feb. 18, 2010, to discuss key challenges related to the premarket notification, or 510(k) process, used to review and clear certain medical devices marketed in the United States. The FDA receives more than 3,000 510(k) submissions each year.
The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Carlyle Hall, MD 110 Irving St Nw Ste 4b39, Washington, DC 20010-3017 Ph: (202) 877-5190 | Erin Carlyle Hall, MD 110 Irving St Nw, Washington, DC 20010-3017 Ph: (202) 877-5190 |
News Archive
The monoclonal antibody omalizumab seems to be effective at relieving symptoms for patients with chronic idiopathic urticaria who have not responded to H1-antihistamine therapy, report US researchers.
Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.
The U.S. Food and Drug Administration announced today that it has scheduled a public meeting on Feb. 18, 2010, to discuss key challenges related to the premarket notification, or 510(k) process, used to review and clear certain medical devices marketed in the United States. The FDA receives more than 3,000 510(k) submissions each year.
The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's disease.
› Verified 3 days ago
Dr. Andrea Badillo, MD Surgery Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-2451 Fax: 202-476-4174 | |
Jerome Alain Byam, Surgery Medicare: Accepting Medicare Assignments Practice Location: 1310 Southern Ave Se, Washington, DC 20032 Phone: 202-574-6000 | |
Dr. Steven Macht, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2021 K St Nw, #217, Washington, DC 20006 Phone: 202-887-8120 Fax: 202-887-8288 | |
Earl Hodin, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2151 | |
Dr. Brandon W Propper, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2150 Pennsylvania Ave Nw, Washington, DC 20037 Phone: 202-741-3210 | |
David H Song, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Phc Building, First Floor, Washington, DC 20007 Phone: 202-444-8751 Fax: 202-444-7204 | |
Melissa Martinez Anastacio, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Room 4b42, Washington, DC 20010 Phone: 202-877-7259 Fax: 202-877-7258 |